Furthermore, a phase I clinical trial (NCT03218826) involving AZD8186, a targeted PI3K inhibitor, is currently underway for various advanced solid tumours, including gastric cancer, and it commenced in March 2018. Here, PIK3CA is linked to gastric cancer.